In December 2025 Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, began commercial distribution of LYMPHIR, a targeted immunotherapy for relapsed or refractory Stage I–III cutaneous T-cell lymphoma. Initial sales were executed through a nationwide network of specialty distributors, marking the company’s transition to revenue generation.

For the quarter ended FQ1 2026, consolidated revenue reached $3.9 million as LYMPHIR sales commenced. The company reported a net loss of $8.2 million, an improvement from $9.8 million in the prior-year period, and closed the quarter with $7.7 million in cash and cash equivalents after securing $20.9 million in net equity financing.

Citius Pharma is leveraging an AI-enabled commercial platform to identify and engage a concentrated base of prescribers and improve patient access. The firm has also negotiated Named Patient Programs to make LYMPHIR available in select European and Middle Eastern markets, laying the groundwork for international reach.

Beyond LYMPHIR, the company continues advancing its late-stage pipeline, including Mino-Lok for catheter-related infections and Halo-Lido for hemorrhoids. Investigator-initiated Phase I trials are evaluating LYMPHIR in combination with pembrolizumab and as part of lymphodepletion regimens ahead of CAR-T therapy, targeting potential label expansions.